456 Studies Now Enrolling
A Phase 1/1b, Multicenter, Open-Label, Dose-Escalation Study of FT 2102 as a Single Agent and in Combination with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation
A study for patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome using study drugs FT 2102
| Sponsor: | Forma Therapeutics |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAQ7654 |
| U.S. Govt. ID: | NCT02719574 |
| Contact: | Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
Additional Study Information:
The purpose of this study is to test the safety and effectiveness of an experimental medication, FT-2102, in the treatment of acute myeloid leukemia or myelodysplastic syndrome. Patients will receive either FT-2102 alone or in combination with cytarabine or azacitidine, an approved drug commonly used in the treatment of AML and MDS. Subjects will remain on study until they experience intolerable side effects, their disease worsens, or they or the study doctor decides to stop.
This study is closed
